Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS

被引：0
|
作者：
Kuhnt, Thomas
Schreiber, Andreas
Pirnasch, Anett
Hautmann, Matthias
Hass, Peter
Sieker, Frank
Engenhart-Cabilic, Rita
Richter, Michael
Dellas, Kathrin
Dunst, Juergen
机构：
[1] Univ Rostock, Dept Radiat Oncol, D-18055 Rostock, Germany
[2] Univ Regensburg, Dept Radiotherapy, D-93053 Regensburg, Germany
[3] Otto Von Guericke Univ, Dept Radiotherapy, Magdeburg, Germany
[4] Univ Halle Wittenberg, Dept Radiotherapy, D-06108 Halle, Germany
[5] Univ Marburg, Dept Radiotherapy, Marburg, Germany
[6] Coordinat Ctr Clin Trials, Halle, Germany
[7] Dept Radiat Oncol Kiel, Kiel, Germany
[8] Dept Radiooncol, Lubeck, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6077
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II-trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell head and neck cancer: 5-year end results
    Kuhnt, T.
    Schreiber, A.
    Pirnasch, A.
    Hautmann, M. G.
    Hass, P.
    Sieker, F. P.
    Engenhart-Cabilic, R.
    Richter, M.
    Dellas, K.
    Dunst, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Phase II-trial of Concomitant Hyperfractionated-accelerated Radiotherapy (HART) With Cisplatin (Cis) Plus Cetuximab (Cet) for Locoregionally Advanced Inoperable Squamous Cell Head and Neck Cancer - Early Response and Acute Toxicities
    Kuhnt, T.
    Schreiber, A.
    Pirnasch, A.
    Hipp, M.
    Hass, P.
    Sieker, F.
    Engenhart-Cabillic, R.
    Richter, M.
    Dellas, K.
    Dunst, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S543 - S543
  • [3] Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck cancer: a phase I dose escalation trial
    Kuhnt, T.
    Sandner, A.
    Wendt, T. G.
    Engenhardt-Cabillic, R.
    Lammering, G.
    Flentje, M.
    Grabenbauer, G. G.
    Pirnasch, A.
    Baumann, M.
    Dunst, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck
    Kuhnt, T.
    Sandner, A.
    Wendt, T.
    Engenhart-Cabillic, R.
    Lammering, G.
    Flentje, M.
    Grabenbauer, G.
    Schreiber, A.
    Pirnasch, A.
    Dunst, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (11) : 2284 - 2289
  • [5] Simultaneous hyperfractionated-accelerated radiotherapy (HART) in combination with cisplatin (CIS) and cetuximab (CET) in locally advanced squamous epithelial carcinoma of the head neck area: final results of the phase-1-study
    Kuhnt, T.
    Sandner, A.
    Wendt, T.
    Engenhart-Cabillic, R.
    Lammering, G.
    Flentje, M.
    Grabenbauer, G.
    Schreiber, A.
    Pirnasch, A.
    Baumann, M.
    Dunst, J.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 23 - 23
  • [6] Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck
    Kuhnt, Thomas
    Schreiber, Andreas
    Pirnasch, Anett
    Hautmann, Matthias G.
    Hass, Peter
    Sieker, Frank P.
    Engenhart-Cabillic, Rita
    Richter, Michael
    Dellas, Kathrin
    Dunst, Juergen
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (09) : 733 - 741
  • [7] Radiotherapy, gemcitabine, and cetuximab (RAGE) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A feasibility study
    Specenier, R.
    Van den Weyngaert, D.
    Van Laer, C.
    Vanderveken, O. M.
    Van Gestel, D.
    Verschueren, C.
    Peeters, M.
    Vermorken, J. B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S750 - S750
  • [8] Phase II Study of Cetuximab With Concomitant-boost Radiotherapy (RT) in Japanese Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN)
    Fujii, M.
    Yoshino, T.
    Onozawa, Y.
    Kodaira, T.
    Ota, M.
    Gross, A.
    Tsukuda, M.
    Tahara, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S564 - S565
  • [9] Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Martins, Renato
    Parvathaneni, Upendra
    Sharma, Anand K.
    Raez, Luis E.
    Papagikos, Michael A.
    Yunus, Furhan
    Bauman, Julie E.
    Eaton, Keith D.
    Liao, Jay Justin
    Mendez, Eduardo
    Futran, Neal
    Kurland, Brenda F.
    Wang, David X.
    Xiaoyu, Shawn
    Wallace, Sarah G.
    Hayes, David N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase I-II trial of gefitinib (IRESSA) and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)
    Caponigro, F.
    Franchin, G.
    Rav, V.
    Silvestro, G.
    Morrica, B.
    Romano, C.
    Minatel, E.
    Pepe, S.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 313 - 313
12345